171261
Dorsomorphin
≥95% (HPLC), liquid, AMPK inhibitor, Calbiochem
Synonym(s):
InSolution AMPK Inhibitor, Compound C, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C24H25N5O
CAS Number:
Molecular Weight:
399.49
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
product name
AMPK Inhibitor, Compound C, InSolution, ≥95%, 10 mM, AMPK Inhibitor
Quality Level
Assay
≥95% (HPLC)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
shipped in
wet ice
storage temp.
2-8°C
InChI
1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2
InChI key
XHBVYDAKJHETMP-UHFFFAOYSA-N
General description
A cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo.
Biochem/physiol Actions
Cell permeable: yes
EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo
Primary Target
AMPK
AMPK
Product competes with ATP.
Reversible: yes
Target IC50: 25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively
Packaging
Packaged under inert gas
Warning
Toxicity: Irritant (B)
Physical form
Supplied as a 10 mM (1 mg/250 µl) solution of AMPK Inhibitor, Compound C (Cat. No. 171260) in DMSO.
Reconstitution
Following initial use, aliquot and freeze (-20°C). Once opened, stock solutions are stable for up to 3 months at -20°C.
Other Notes
Hao, J., et al. 2010. ACS Chem.Biol.5, 245.
Kim, E.K., et al. 2004. J. Biol. Chem.279, 19970.
Lee, M., et al. 2003. J. Biol. Chem.278, 39653.
Inoki, K., et al. 2003. Cell115, 577.
Fryer, L.G., 2002. FEBS Lett.531, 189.
Zhou, G., et al. 2001. J. Clin. Invest.108, 1167.
Kim, E.K., et al. 2004. J. Biol. Chem.279, 19970.
Lee, M., et al. 2003. J. Biol. Chem.278, 39653.
Inoki, K., et al. 2003. Cell115, 577.
Fryer, L.G., 2002. FEBS Lett.531, 189.
Zhou, G., et al. 2001. J. Clin. Invest.108, 1167.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
188.6 °F - closed cup - (Dimethylsulfoxide)
Flash Point(C)
87 °C - closed cup - (Dimethylsulfoxide)
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Yao-Yao Chang et al.
Frontiers in immunology, 13, 820524-820524 (2022-03-01)
P2Y1 receptor is a G-protein-coupled receptor that plays a critical role in the immune response of inflammatory bowel diseases. However, its regulatory effects on CD4+ T cell response have not been fully elucidated. The study aimed to characterize the role
Reetta A E Eriksson et al.
Frontiers in medicine, 9, 1052318-1052318 (2022-12-31)
Gene therapy would greatly benefit from a method to regulate therapeutic gene expression temporally. Riboswitches are small RNA elements that have been studied for their potential use in turning transgene expression on or off by ligand binding. We compared several
Ernesto Pena Calderin et al.
Molecular metabolism, 66, 101637-101637 (2022-11-19)
Physical activity has been shown to reduce the risk of CVD mortality in large-cohort longitudinal studies; however, the mechanisms underpinning the beneficial effects of exercise remain incompletely understood. Emerging data suggest that the risk reducing effect of exercise extends beyond
Yidi Wang et al.
Cells, 11(19) (2022-10-15)
Crouzon syndrome ([OMIM] #123500) caused by FGFR2 mutation is an autosomal dominant syndrome with craniosynostosis, the underlying mechanism of which remains obscure. First, whole exome sequencing was used to screen the possible pathogenic variant in two sporadic patients with Crouzon
Xiaochen Yu et al.
Frontiers in physiology, 13, 817542-817542 (2022-03-19)
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug; however, the effects of empagliflozin on hepatic gluconeogenesis
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service